Type I Interferon as cardiovascular risk factor in systemic and cutaneous lupus erythematosus: A systematic review
Autor: | Kylie Thaler, Emma Husar-Memmer, Ruth D E Fritsch-Stork, K. Rappersberger, Chiara Kirchler |
---|---|
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Immunology Disease 03 medical and health sciences 0302 clinical medicine Interferon Risk Factors Internal medicine Lupus Erythematosus Cutaneous Immunology and Allergy Medicine Humans Lupus Erythematosus Systemic Platelet activation Myocardial infarction Risk factor Endothelial dysfunction skin and connective tissue diseases 030203 arthritis & rheumatology business.industry medicine.disease Fibroblast Growth Factor-23 030104 developmental biology Cardiovascular Diseases Heart Disease Risk Factors Interferon Type I Cutaneous Lupus Erythematosus business Mace medicine.drug |
Zdroj: | Autoimmunity reviews. 20(5) |
ISSN: | 1873-0183 |
Popis: | Objective Patients with systemic lupus erythematosus (SLE) have a high burden of cardiovascular disease (CVD) of multifactorial origin. The aim of this systematic review is to analyze the role of the interferon I (IFN-I) signature and fibroblast growth factor-23 (FGF-23) in patients with SLE or cutaneous lupus erythematosus (CLE) herein. Materials and methods We conducted a systematic literature search in PubMed and Scopus using keywords for major adverse cardiovascular events (MACE) and intermediate outcomes (endothelial dysfunction, subclinical atherosclerosis, platelet activation) associated with IFN-I or FGF-23 in patients with SLE and CLE. Results 4745 citations were screened, of which 12 studies were included. IFN-I was associated with MACE in two third of the studies and the association was strongest for cardiac events. An association of IFN-I was found in all studies investigating impaired vascular function, but only in 50% (respectively 40%) of reports examining the relation of IFN-I and platelet activation (respectively subclinical atherosclerosis). Altogether the reports were of variable bias and quality due to high variability of examined IFN-I biomarkers and inconsistent results for different outcome measures. No studies investigating the cardiovascular risk of circulating IFN-I in CLE, nor FGF-23 in SLE or CLE were found. Conclusion Clinical studies measuring the association between IFN-I and direct / intermediate measures of CVD are rare and ambiguous in SLE and nonexistent in CLE, hampering a definite conclusion. |
Databáze: | OpenAIRE |
Externí odkaz: |